ÂÜÀòÂÒÂ×

Justin Mika serves as the Chief Executive Officer of AbTherx since June 2023, contributing to advancements in therapeutic antibody discovery through innovative technologies. Currently, Mika also holds a position as a Board Member at PhenoVista Biosciences, a leader in advanced phenotypic assay services. Previously, Mika was the Chief Executive Officer of AlivaMab Discovery Services LLC, where the focus was on enhancing antibody discovery programs for partners. Mika's extensive experience spans various roles at Eurofins Discovery and Eurofins DiscoverX, including Senior Vice President, where responsibilities included strategic direction across global sites. Early career roles include territory management at Thomas Scientific and research technician at Princeton University. Mika holds a Bachelor of Science in Science with a focus in Biochemistry and Molecular Biology from Penn State University and two master's degrees in Organizational Development and Business Administration from the University of Delaware.